Cardiovascular disease remains a leading cause of death and morbidity in the United States despite impressive gains in diagnostics, prevention, and treatment. The 2013 URMC Cardiology for Clinicians Spring Symposium will provide expert reviews of key advances and state of the art discussions of cardiovascular care clinicians require.
The program begins with an update on the clinical evaluation of pulmonary hypertension and diastolic heart failure, a topic of great interest to the medical center community challenged to reduce heart failure readmission rate in the current era of capitated reimbursements for heart failure treatment in hospital. With the increase in anti-platelet medications approved for clinical use since guidelines have been published, a complete, expert detailed review of the use of anti-platelet medications in cardiovascular practice will be provided. Many patients in our community live with the morbid burden of severe aortic stenosis and are not candidates for aortic valve replacement surgery. To address the need to educate the medical community about new curative treatment options for these patients, an update of the latest indications, procedures and outcomes of the URMC program for transcatheter aortic valve intervention (TAVI) will be provided from the perspective of both the invasive cardiologist and the cardiac surgeon.
The symposium will address the need to provide rapid, low-cost, low dose stress only cardiac imaging for efficient evaluation of ED patients, and the opportunity for reliable cardiac evaluation of morbidly obese and super obese patients with the use of high speed CZT SPECT imaging which is now routinely available at URMC Cardiology and a limited number of advanced heart centers in the United States and throughout the world. This program addresses the need to provide case based reviews for the medical community of advances in the evidence for the use of inflammatory markers as an indication for statin therapy, cost and benefits of strain imaging in echocardiography, and the status of hormone replacement therapy for women in 2013. Popular small group workshops to present challenging diagnostic cases in noninvasive cardiology, women’s heart health, and electrophysiology will be provided. To address the under-utilization of implantable cardiac defibrillators and biventricular pacemakers, Dr. Arthur Moss, principal investigator of the MADIT trial, will deliver a keynote address on understanding the costs and benefits of advances in implantable cardiac defibrillators and cardiac resynchronization therapy in 2013. At the conclusion of this program, participants should be able to:
Presented by both community- and world renowned experts in their fields, the 2013 URMC Cardiology for Clinicians Spring Symposium provides new opportunities for understanding advances in cardiovascular care required in daily practice.
- List advances in rapid, cost effective, and ultra low dose radiation exposure cardiac imaging
- Explain the key advantages of image quality and diagnostic accuracy of CZT SPECT compared to conventional SPECT myocardial perfusion imaging and other CAD risk assessment strategies in the morbidly obese and super-obese patient population (BMI 30-66)
- Identify cost and benefits of contrast and strain imaging in echocardiography
- Recognize costs and benefits of advances in implantable defibrillator and cardiac resynchronization therapy